- Home
- MHO vs RYTM Comparison
MHO vs RYTM Comparison
Compare MHO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- RYTM
- Stock Information
- Founded
- MHO 1976
- RYTM 2008
- Country
- MHO United States
- RYTM United States
- Employees
- MHO N/A
- RYTM N/A
- Industry
- MHO Homebuilding
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MHO Consumer Discretionary
- RYTM Health Care
- Exchange
- MHO Nasdaq
- RYTM Nasdaq
- Market Cap
- MHO 3.1B
- RYTM 3.8B
- IPO Year
- MHO 1986
- RYTM 2017
- Fundamental
- Price
- MHO $106.57
- RYTM $61.33
- Analyst Decision
- MHO Strong Buy
- RYTM Strong Buy
- Analyst Count
- MHO 3
- RYTM 12
- Target Price
- MHO $158.67
- RYTM $76.75
- AVG Volume (30 Days)
- MHO 211.1K
- RYTM 632.6K
- Earning Date
- MHO 04-23-2025
- RYTM 05-07-2025
- Dividend Yield
- MHO N/A
- RYTM N/A
- EPS Growth
- MHO 9.13
- RYTM N/A
- EPS
- MHO 18.93
- RYTM N/A
- Revenue
- MHO $4,434,060,000.00
- RYTM $136,863,000.00
- Revenue This Year
- MHO $0.74
- RYTM $37.88
- Revenue Next Year
- MHO $0.62
- RYTM $72.84
- P/E Ratio
- MHO $5.63
- RYTM N/A
- Revenue Growth
- MHO 8.69
- RYTM 48.88
- 52 Week Low
- MHO $100.22
- RYTM $35.35
- 52 Week High
- MHO $176.18
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- MHO 44.80
- RYTM 51.78
- Support Level
- MHO $105.74
- RYTM $58.72
- Resistance Level
- MHO $109.84
- RYTM $63.24
- Average True Range (ATR)
- MHO 3.04
- RYTM 2.43
- MACD
- MHO -0.28
- RYTM -0.15
- Stochastic Oscillator
- MHO 18.72
- RYTM 65.51
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.